A Real World Study For the Efficacy and Safety of Large Dose Tanreqing Injection in the Treatment of Patients with Novel Coronavirus Pneumonia (COVID-19)

The First Afflicated Hospital of Guangzhou University of Chinese Medicine0 个研究点开始时间: 待定最近更新: 2023年2月20日

试验速览

暂无简介。

•1. Confirmed or suspected cases who are comply with the diagnostic criteria for pneumonia caused by novel coronavirus infection in the Diagnosis and Treatment Program for pneumonia caused by novel coronavirus infection (Trial Version 4);
•2. Inpatients aged 18-75 years;
•3. Obtain the informed consent form.

•1. Patients with severe novel coronavirus pneumonia;
•2. Patients with severe basic diseases;
•3. Patients who have mental confusion, pregnant or lactating women, who with a history of drug abuse or dependence, who allergic to study medication, who have participated in another clinical trial within 3 months,or who have other conditions not suitable for clinical study.

发起方

The First Afflicated Hospital of Guangzhou University of Chinese Medicine